The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles
Open accessAbstract
Cisplatin is used to treat a variety of tumors, but dose limiting toxicities or intrinsic and acquired resistance limit its application in many types of cancer including prostate. We report a unique strategy to deliver cisplatin to prostate cancer cells by constructing Pt(IV)-encapsulated prostate-specific membrane antigen (PSMA) targeted nanoparticles (NPs) of poly(D,L-lactic- co -glycolic acid) (PLGA)-poly(ethylene glycol) (PEG)-functionalized controlled release polymers. By using PLGA- b -PEG nanoparticles with PSMA targeting aptamers (Apt) on the surface as a vehicle for the platinum(IV) compound c,t,c -[Pt(NH 3 ) 2 (O 2 CCH 2 CH 2 CH 2 CH 2 CH 3 ) 2 Cl 2 ] ( 1 ), a lethal dose of cisplatin was delivered specifically to prostate cancer cells. PSMA aptamer targeted delivery of Pt(IV) cargos to PSMA + LNCaP prostate cancer cells by endocytosis of the nanoparticle vehicles was demonstrated using fluorescence microscopy by colocalization of green fluorescent labeled cholesterol-encapsulated NPs and early endosome marker EEA-1. The choice of linear hexyl chains in 1 was the result of a systematic study to optimize encapsulation and controlled release from the polymer without compromising either feature. Release of cisplatin from the polymeric nanoparticles after reduction of 1 and formation of cisplatin 1,2-intrastrand d(GpG) cross-links on nuclear DNA was confirmed by using a monoclonal antibody for the adduct. A comparison between the cytotoxic activities of Pt(IV)-encapsulated PLGA- b -PEG NPs with the PSMA aptamer on the surface (Pt-NP-Apt), cisplatin, and the nontargeted Pt(IV)-encapsulated NPs (Pt-NP) against human prostate PSMA-overexpressing LNCaP and PSMA - PC3 cancer cells revealed significant differences. The effectiveness of PSMA targeted Pt-NP-Apt nanoparticles against the PSMA + LNCaP cells is approximately an order of magnitude greater than that of free cisplatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Self-citationNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Self-citationBiodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Self-citationNanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J., Wang, A., Langer, R., & Farokhzad, O. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,657
Self-citationNanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
(2016) · CRC Press eBooks · doi:10.1201/b12801 · Cited by 2,031
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Self-citationSmall-scale systems for in vivo drug delivery
LaVan, D. A., McGuire, T., & Langer, R. (2003) · Nature Biotechnology · doi:10.1038/nbt876 · Cited by 1,304
Self-citationTemporal targeting of tumour cells and neovasculature with a nanoscale delivery system
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., & Sasisekharan, R. (2005) · Nature · doi:10.1038/nature03794 · Cited by 945
Nanoparticle-Aptamer Bioconjugates
Farokhzad, O. C., Jon, S., Khademhosseini, A., Tran, T.-N. T., LaVan, D. A., & Langer, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2550 · Cited by 897
Self-citationChang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S., & Gaudin, P. B. (1999) · PubMed · Cited by 825
Nanoscale Coordination Polymers for Platinum-Based Anticancer Drug Delivery
Rieter, W. J., Pott, K. M., Taylor, K. M. L., & Lin, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803383k · Cited by 803
Dhar, S., Liu, Z., Thomale, J., Dai, H., & Lippard, S. J. (2008) · Journal of the American Chemical Society · doi:10.1021/ja803036e · Cited by 700
Self-citationUpregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Feazell, R. P., Nakayama-Ratchford, N., Dai, H., & Lippard, S. J. (2007) · Journal of the American Chemical Society · doi:10.1021/ja073231f · Cited by 616
Self-citationLanger, R. (2001) · Science · doi:10.1126/science.1063273 · Cited by 579
Self-citationLupold, S. E., Hicke, B. J., Lin, Y. H., & Coffey, D. S. (2002) · PubMed · Cited by 566
Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Fair, W. R., & Heston, W. D. W. (1993) · PubMed · Cited by 541
Avgoustakis, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00530-2 · Cited by 503
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto, J. T., Suffoletto, B. P., Berzin, T. M., Qiao, C. H., Lin, S., Tong, W. P., May, F., Mukherjee, B., & Heston, W. D. W. (1996) · PubMed · Cited by 389
In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin–PLGA conjugates
Yoo, H. S., Lee, K. H., Oh, J. E., & Park, T. G. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00280-7 · Cited by 374
Chorny, M., Fishbein, I., Danenberg, H. D., & Golomb, G. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00211-0 · Cited by 370
Yokoyama, M. (1998) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00115-6 · Cited by 308
Barnes, K. R., Kutikov, A., & Lippard, S. J. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.03.024 · Cited by 263
Self-citationGiandomenico, C. M., Abrams, M. J., Murrer, B. A., Vollano, J. F., Rheinheimer, M. I., Wyer, S. B., Bossard, G. E., & Higgins, J. D. (1995) · Inorganic Chemistry · doi:10.1021/ic00109a004 · Cited by 248
Water soluble polymers in tumor targeted delivery
Kopeček, J., Kopečková, P., Minko, T., Lu, Z.-R., & Peterson, C. M. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00330-3 · Cited by 227
Conjugated Platinum(IV)−Peptide Complexes for Targeting Angiogenic Tumor Vasculature
Mukhopadhyay, S., Barnés, C. M., Haskel, A., Short, S. M., Barnes, K. R., & Lippard, S. J. (2008) · Bioconjugate Chemistry · doi:10.1021/bc070031k · Cited by 226
Self-citationRawlings, N. D. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.343 · Cited by 221
Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Sheehan, C. E., Vallabhajosula, S., Goldsmith, S. J., Ross, J. S., & Bander, N. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.8097 · Cited by 217
Kawakami, M., & Nakayama, J. (1997) · PubMed · Cited by 203
Murphy, G. P., Elgamal, A. A., Su, S. L., et al. (1998) · PubMed · Cited by 168
Hall, M. D., Dillon, C. T., Zhang, M., Beale, P. J., Cai, Z., Lai, B. C. H., Stampfl, A. P. J., & Hambley, T. W. (2003) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-003-0471-6 · Cited by 157
Murphy, G. P., Elgamal, A. A., Su, S. L., Bostwick, D. G., & Holmes, E. H. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2259::aid-cncr5>3.0.co;2-t · Cited by 150
Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells
Gryparis, E. C., Hatziapostolou, M., Papadimitriou, Ε., & Avgoustakis, K. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.12.017 · Cited by 139
Liedert, B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl051 · Cited by 115
Zhang, Z., & Feng, S. (2006) · Biomacromolecules · doi:10.1021/bm050953v · Cited by 88
Stolnik, S., Heald, C. R., Neal, J. C., Garnett, M. C., Davis, S. S., Illum, L., Purkiss, S. C., Barlow, R. J., & Gellert, P. R. (2001) · Journal of drug targeting · doi:10.3109/10611860108998772 · Cited by 82
Fujiyama, J., Nakase, Y., Osaki, K., Sakakura, C., Yamagishi, H., & Hagiwara, A. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00131-7 · Cited by 63
Characterization of cisplatin cytotoxicity delivered from PLGA-systems
Moreno, D., de Ilarduya, C. T., Bandrés, E., Buñuales, M., Azcona, M., Garcia-Foncillas, J., & Garrido, M. J. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.08.006 · Cited by 43
Cited by
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
“Various mechanisms of targeted delivery of drugs from diblock nanoparticles have also been reported [18,23,24].”
BackgroundPEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Metadata
- Authors
- Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., & Lippard, S. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-11-11
- Volume
- 105
- Issue
- 45
- Pages
- 17356-17361
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2129360146
- Cited by
- 994
- References
- 44
- FWCI
- 20.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.